




[圖1]




[圖2]




[圖3]




[圖4]



[圖5]




[도6]



** & ***, $p < 0.01$ & < 0.001 vs NASH Co.

###, $p < 0.001$ vs Combo


[도7]




***, $p < 0.001$ vs. NASH Co.

###, $p < 0.001$ vs. Combo

[도8]




[도9]




[010]


#, $p < 0.05$ vs. Normal Co.
*, $p < 0.05$ vs. NASH Co.




[도 11]



[도 12]



[圖13]



Treatment		GPR119 agonist	PPAR agonist	ACC inhibitor	FXR agonist
		Compound 1	Elafibranor	Firsocostat	Obeticholic Acid
IC ₃₀ (μM)	Alone	0.53	5.04	2.88	4.02
	+0.3 μM Compd 1	-	0.59	0.04	1.85
Combination Index (CI)		-	0.7	0.6	1.0